Structure-Activity Relationships of Antitubercular Nitroimidazoles. 1. Structural Features Associated with Aerobic and Anaerobic Activities of 4-and 5-Nitroimidazoles

被引:89
作者
Kim, Pilho [1 ]
Zhang, Liano [1 ]
Manjunatha, Ujjini H. [1 ]
Singh, Ramandeep [1 ]
Patel, Sejal [2 ]
Jiricek, Jan [2 ]
Keller, Thomas H. [2 ]
Boshoff, Helena I. [1 ]
Barry, Clifton E., III [1 ]
Dowd, Cynthia S. [1 ]
机构
[1] NIAID, TB Res Sect, Lab Clin Infect Dis, NIH, Bethesda, MD 20892 USA
[2] Novartis Inst Trop Dis, Singapore 138670, Singapore
基金
英国惠康基金;
关键词
IN-VITRO; NITROFURANYLAMIDES; TUBERCULOSIS; PROSPECTS; PA-824; SERIES;
D O I
10.1021/jm801246z
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
The 4-nitroimidazole PA-824 is active against aerobic and anaerobic Mycobacterium tuberculosis (Mtb) while 5-nitroimidazoles like metronidazole are active against only anaerobic Mtb. We have synthesized analogues of both 4- and 5-nitroimidazoles and explored their antitubercular activities. The nitro group is required for both activities in all compounds. The key determinants of aerobic activity in the 4-nitroimidazoles include the bicyclic oxazine, the lipophilic tail, and the 2-position oxygen. For the 5-nitroimidazoles. neither the corresponding bicyclic analogue not-addition of a lipophilic tail conveyed aerobic activity. Incorporation of a 2-position oxygen atom into a rigid 5-nitroimidazooxazine provided the first 5-nitroimidazole with aerobic activity. Across both series, anaerobic and aerobic activities were not correlated and Mtb mutants lacking the deazaflavin-dependent nitroreductase (Ddn) retained anaerobic sensitivity to some Compounds. Aerobic activity appears to be correlated with efficiency as a substrate for Ddn, suggesting a means of structure-based optimization of improved nitroimidazoles.
引用
收藏
页码:1317 / 1328
页数:12
相关论文
共 29 条
[1]   POTENTIAL RADIOSENSITIZING AGENTS - DINITROIMIDAZOLES [J].
AGRAWAL, KC ;
BEARS, KB ;
SEHGAL, RK ;
BROWN, JN ;
RIST, PE ;
RUPP, WD .
JOURNAL OF MEDICINAL CHEMISTRY, 1979, 22 (05) :583-586
[2]   INVITRO AND INVIVO ACTIVITIES OF THE NITROIMIDAZOLE CGI-17341 AGAINST MYCOBACTERIUM-TUBERCULOSIS [J].
ASHTEKAR, DR ;
COSTAPERIRA, R ;
NAGRAJAN, K ;
VISHVANATHAN, N ;
BHATT, AD ;
RITTEL, W .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1993, 37 (02) :183-186
[3]  
Baker W. R. S. C., 2000, U.S. Patent, Patent No. 6087358
[4]  
Baker W. R. S. C., 1997, U.S. Patent, Patent No. [5,668,127, 5668127]
[5]   Prospects for clinical introduction of nitroimidazole antibiotics for the treatment of tuberculosis [J].
Barry, CE ;
Boshoff, HIM ;
Dowd, CS .
CURRENT PHARMACEUTICAL DESIGN, 2004, 10 (26) :3239-3262
[6]   Tuberculosis - Metabolism and respiration in the absence of growth [J].
Boshoff, HIM ;
Barry, CE .
NATURE REVIEWS MICROBIOLOGY, 2005, 3 (01) :70-80
[7]   Cross-metathesis reaction. Generation of highly functionalized olefins from unsaturated alcohols [J].
Cossy, J ;
BouzBouz, S ;
Hoveyda, AH .
JOURNAL OF ORGANOMETALLIC CHEMISTRY, 2001, 624 (1-2) :327-332
[8]  
Dick T, 1998, FEMS MICROBIOL LETT, V163, P159, DOI 10.1016/S0378-1097(98)00166-9
[9]   Prospects for new antitubercular drugs [J].
Duncan, K ;
Barry, CE .
CURRENT OPINION IN MICROBIOLOGY, 2004, 7 (05) :460-465
[10]   Synthesis of fused bicyclic imidazoles by sequential van Leusen/ring-closing metathesis reactions [J].
Gracias, V ;
Gasiecki, AF ;
Djuric, SW .
ORGANIC LETTERS, 2005, 7 (15) :3183-3186